Additional Family of CombiCult Patents Granted in USA, Europe, Australia and Singapore
Plasticell, the biotechnology company developing regenerative drugs using high throughput stem cell technologies, has announced that a further family of patents, offering additional protection of its proprietary cell culture technology, Combinatorial Cell Culture (CombiCult), has been granted by the US Patent Office, European Patent Office, Australian Patent Office and Intellectual Property Office of Singapore.
The newly granted patents cover the use of nanomaterial tags to track the cell culture history of cells grown on beads and exemplify use of the method to deduce optimal culture conditions for the differentiation of stem cells. ‘These patents provide a secondary layer of coverage for Plasticell’s platform technology and extend the lifespan of patent protection,’ said Dr Yen Choo, founder and Executive Chairman of Plasticell and inventor of the methods.
Combinatorial Cell Culture forms the basis of the company’s CombiCult system for high throughput screening of stem cell differentiation protocols. CombiCult allows researchers to rapidly identify and/or optimise novel protocols which are highly efficient and/or cost-effective, free of undesirable media components such as serum, and to replace growth factors with small molecules.
Plasticell forms collaborations with industry partners to use CombiCult in the production of rare cell types for research or therapy applications.
Related News
-
News Women in Pharma: Moving beyond discussions and into best practice at CPHI Milan
In this second CPHI Milan special of our monthly series, we cover the key takeaways from the Diversity & Wellbeing track held on October 10, 2024. -
News AstraZeneca invests in AI collaboration for cancer drug trials
The British-Swedish pharmaceutical giant is partnering with biotechnology firm Immunai Inc to increase the efficiency of some cancer drug trials. -
News Ozempic and Wegovy prices questioned as Novo Nordisk faces US Senate hearing
The CEO of Novo Nordisk was grilled during a US Senate committee hearing on September 24, 2024, in which the exorbitant prices of the Danish company’s blockbuster drugs Ozempic and Wegovy were called into question. -
News The BIOSECURE Act: implications for the pharma supply chain
On September 9, 2024, the US House of Representatives voted to pass the bill titled the BIOSECURE Act (the Act), which lists several Chinese companies in the pharmaceutical supply chain. The Act will prohibit American companies from contracting or doin... -
News On Track at CPHI Milan: Thermo Fisher Scientific Track Sponsor interview
With CPHI Milan just around the corner, we sat down with some of the sponsors for this year’s conference tracks to discuss the most pressing topics in pharma. -
News CPHI Milan Speaker Spotlight: Pharma Manufacturing and Localisation in Africa
In the run-up to CPHI Milan, we sit down with some of the experts and thought-leaders speaking at this year’s conferences. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Eli Lilly licenses rheumatoid arthritis manufacturing in Africa
American pharmaceutical company Eli Lilly has signed a partnership with Egyptian organisation Eva Pharma to localise manufacturing of rheumatoid arthritis treatments in Africa.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance